Compare ACEL & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACEL | JANX |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 964.6M | 1.0B |
| IPO Year | 2017 | 2021 |
| Metric | ACEL | JANX |
|---|---|---|
| Price | $10.95 | $16.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 18 |
| Target Price | $15.71 | ★ $36.24 |
| AVG Volume (30 Days) | 387.7K | ★ 746.1K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.34 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $8.34 | $194.24 |
| Revenue Next Year | $4.28 | N/A |
| P/E Ratio | $34.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.55 | $12.12 |
| 52 Week High | $14.00 | $35.34 |
| Indicator | ACEL | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 44.53 | 45.68 |
| Support Level | $10.67 | $15.83 |
| Resistance Level | $11.47 | $19.16 |
| Average True Range (ATR) | 0.25 | 0.91 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 30.00 | 16.32 |
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.